Compare Liberty Global Ltd Class C (LBTYK) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Sana Biotechnology Inc — how do they compare? Liberty Global Ltd Class C trades at $10 (market cap $3.47B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Liberty Global Ltd Class C is far larger — about 4× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| LBTYK | SANA | |
|---|---|---|
Market Cap | $3.47B | $873.84M |
Sector | Technology | Health |
52-Week High | $12.67 | $5.92 |
52-Week Low | $10.00 | $2.68 |
Enterprise Value | $10.75B | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LBTYK trades at $9.995, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion for 2025, though revenue grew to $4.88 billion. Recent news highlights strategic moves, including the planned 2027 Amsterdam listing of Ziggo Group. Analyst consensus is strongly positive, with 69% recommending Buy.
The outlook hinges on execution of the Ziggo Group spin-off, a potential value catalyst. However, persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. The stock offers a deep value opportunity if management delivers on restructuring, but operational turnaround is critical for sustained recovery.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
